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Abstract Members of the Cool protein family contain SH3,
Dbl, and pleckstrin homology domains and are binding partners
for the p21-activated kinase (PAK). Using the yeast two-hybrid
screen, we identi¢ed Cbl-b as a Cool family binding partner. We
co-immunoprecipitated endogenous Cool and Cbl-b from a vari-
ety of breast cancer cell lines. The Cool^Cbl-b interaction re-
quires the SH3 domain of Cool and competes with the binding
of PAK to Cool proteins. Expression of Cbl-b e¡ectively blocks
the ability of Cool-2 to stimulate PAK, thus providing an addi-
tional mechanism, aside from catalyzing receptor ubiquitination,
by which Cbl-b acts as a negative regulator for signaling activ-
ities requiring PAK activation.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
A number of lines of evidence indicate that growth factor-
coupled signaling pathways utilize GTP-binding proteins
which serve as molecular switches to activate speci¢c target/
e¡ector activities. In addition to the well known coupling
between receptor tyrosine kinases and Ras, it has recently
become appreciated that members of the Rho subfamily,
and in particular Cdc42 and Rac, are sensitive to growth
factor activation and are able to initiate signaling cascades
that lead to the nucleus [1^3]. One of the best known targets
for Cdc42 and Rac are members of the p21-activated kinase
(PAK) family of serine/threonine kinases [4^7]. Stimulation of
PAK by Cdc42/Rac can trigger a series of signaling events
that culminate in the activation of stress-responsive mitogen-
activated protein (MAP) kinases, including the c-Jun kinase
and p38 [8^12]. PAK activity has also been implicated in
various actin cytoskeletal rearrangements and in alterations
in cell morphology, thus providing a potential control point
for linking signals to the nucleus with those in£uencing cell
shape and motility [13^16].
Given the fact that PAK is a predominant signaling target/
e¡ector for Cdc42 and Rac, and because it apparently can
in£uence a number of cellular activities, it seemed likely that
PAK activity would be tightly regulated in cells. In order to
learn more about the underlying mechanisms responsible for
the regulation of PAK activity, as well as gain additional in-
sights into the signaling pathways utilizing PAK, we set out to
search for PAK-binding partners. This led us to a family of
proteins that we originally named Cool (for cloned out of
library [17]). The Cool proteins all contain an SH3 domain
followed by Dbl homology and pleckstrin homology (PH)
domains. We have characterized three members of the family
in detail, the ¢rst being a 50 kDa protein, p50Cool-1, which
binds via its SH3 domain to a stretch of proline residues with-
in the amino-terminal regulatory half of the PAK molecule
and acts as a negative regulator of PAK activity [17]. A some-
what longer splice variant form of p50Cool-1, designated
p85Cool-1 (identical to L-Pix for PAK-interactive exchange
factor [18]) and p85SPR [19], neither inhibits nor directly ac-
tivates PAK, while a third related protein, p90Cool-2 (identi-
cal to K-Pix [18] and referred to from here on as Cool-2),
strongly stimulates PAK activity as a result of its catalyzing
the guanine nucleotide exchange activity of Rac (Feng et al.,
unpublished data), as well as possibly through its direct bind-
ing to the kinase [20].
In this work, we show that members of the Cbl (Casitas B
lymphoma) family of proteins represent a new class of Cool-
binding partners. The c-Cbl protein represents the cellular
homolog of the viral transforming protein of the murine
Cas NS-1 retrovirus, which contains the amino-terminal 355
amino acids of c-Cbl, including a nuclear localization signal
[21]. It is also V55% identical to the Caenorhabditis elegans
sli-1 gene product, which antagonizes the actions of the let-23
gene product (i.e. the epidermal growth factor (EGF) receptor
homolog) in the signaling pathway responsible for vulval de-
velopment [22]. It was originally suspected that c-Cbl might
have a hematopoietic-speci¢c function, as it was shown to be
tyrosine phosphorylated in Jurkat T cells upon T cell receptor
activation, as well as transiently tyrosine phosphorylated in
macrophages after colony-stimulating factor-1 stimulation
[23,24]. However, it was subsequently shown to be tyrosine
phosphorylated in an EGF-dependent manner and thought to
serve as some type of sca¡old in EGF-coupled signaling, given
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that it was composed of a number of distinct domains includ-
ing a nuclear localization sequence, as well as SH2, ring-¢n-
ger, leucine-zipper and proline-rich domains.
Recently, it has also been reported that the Cbl proteins
have E3 ubiquitin ligase activity and participate in the degra-
dation of EGF receptors [25,26], which may at least in part
contribute to their negative regulatory e¡ects on EGF recep-
tor-coupled signaling. Here, we demonstrate that the c-Cbl
homolog, Cbl-b, which was originally cloned from a breast
cancer cell library and is enriched in breast cancer cells [27],
forms a stable complex with the Cool proteins through their
common SH3 domain. We show that Cbl-b competes with
PAK for binding to the Cool proteins and that this results
in an inhibition of PAK activity. Thus, the ability of Cbl-b to
bind the Cool/Pix proteins o¡ers an additional mechanism by
which it can negatively regulate EGF receptor-coupled signal-
ing activities, by inhibiting the Cool-2/K-Pix-mediated activa-
tion of PAK and its ability to signal downstream of the stress-
responsive nuclear MAP kinases.
2. Materials and methods
2.1. Cell culture, antibodies and other reagents
MDA-MB 453 and 468 human mammary carcinoma cells were
kindly provided by Dr. Mark Sliwkowski (Genentech). SKBR3,
BT20, and MDA-MB-231 human mammary carcinoma cells were
purchased from ATCC. All cell lines were grown in Dulbecco’s modi-
¢ed Eagle’s medium plus 10% fetal bovine serum. Myc-tagged
p85Cool-1 and the SH3-binding-defective mutant Myc-p85Cool-
1(W43K) were prepared as described in Bagrodia et al. [17]. The hem-
agglutinin (HA)-tagged Cbl-b construct was a kind gift from Dr. Stan
Lipkowitz (National Cancer Institute, Bethesda, MD, USA). The HA-
tagged c-Cbl construct was prepared by inserting the cDNA encoding
c-Cbl (a kind gift from Dr. Wallace Langdon, Queen Elizabeth Med-
ical Center, Australia) into pGEM4Z. The Cbl-b construct lacking the
proline-rich domain (residues 1^418; designated Cbl-b-RF) was pre-
pared using the polymerase chain reaction (PCR), followed by sub-
cloning the PCR product into HA-pcDNA3. The PAK3 construct
lacking the kinase domain (residues 1^327; designated PAK(KD))
was also generated by PCR and subcloning into HA-pcDNA3.
Anti-c-Cbl and anti-Cbl-b antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Anti-Cool antibody was prepared
using hexa-histidine (His)-tagged p50Cool-1 that was treated with
thrombin to remove the His tag and then puri¢ed on a Mono Q-
Sepharose column [17]. HA-tagged proteins were immunoprecipitated
and/or Western blotted with monoclonal antibody (mAb) 12CA5 as-
cites or CA-11 (Babco), and Myc-tagged proteins were immunopreci-
pitated and/or Western blotted with mAb 9E10.
2.2. Yeast two-hybrid screen
The yeast strain L40 was co-transformed with p50Cool-1 fused to
the LexA DNA-binding domain, which regulates expression of both
his3 and lacZ, and a Jurkat cDNA library fused with the Gal4 acti-
vation domain [28]. Clones positive for L-galactosidase activity were
rescued, and a partial clone was sequenced and shown to be identical
to a region within the carboxy-terminal half of the Cbl-b protein (see
Section 3).
2.3. Cell lysis and kinase assays
Cells were washed with cold phosphate-bu¡ered saline, and lysed in
20 mM HEPES, pH 7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM
EDTA, 1 mM sodium vanadate, 10 Wg/ml leupeptin, and 10 Wg/ml
aprotinin. The lysates were then centrifuged at 12 000 rpm for 25 min
at 4‡C.
PAK3 assays were performed as follows. The amounts of PAK3 in
the lysates were determined by Western blotting. Lysates containing
essentially equivalent amounts of PAK3 were immunoprecipitated
with an anti-PAK3 primary antibody (a gift from Dr. S. Pelech,
Kinetek Biotechnology, Vancouver, BC, Canada) for 1^2 h followed
by incubation with protein A-Sepharose for an additional hour. Im-
munoprecipitates were washed (three times) with lysis bu¡er and then
with 2Ukinase bu¡er (40 mM HEPES, pH 7.4, 20 mM MgCl2, and
4 mM MnCl2). Myelin basic protein (MBP; Sigma) was then used as
a phosphorylation substrate (5 Wg). The kinase reactions were initiated
by the addition of kinase bu¡er and 20 WM [Q-32P]ATP (3000 Ci/
mmol) for 5 min at room temperature. The kinase reactions were
stopped by the addition of 2Usodium dodecyl sulfate (SDS) sample
bu¡er containing 20 mM EDTA. Proteins eluted by boiling for 2^5
min were resolved by 12.5% SDS^polyacrylamide gel electrophoresis.
The proteins were transferred to Immobilon P membranes (Millipore)
and autoradiographed prior to immunoblotting. The blots were
probed with anti-HA, anti-Myc, anti-Cool, or anti-PAK3 antibodies.
The primary antibodies were detected with horseradish peroxidase-
coupled sheep anti-mouse or donkey anti-rabbit antibody by ECL
(Amersham Pharmacia Biotech).
3. Results and discussion
We have used the yeast two-hybrid screen to identify bind-
ing partners for the PAK and Cool proteins. The Cool pro-
teins (p50Cool-1 and p85Cool-1) were originally identi¢ed
from this screen as binding partners for PAK3 [17]. We
then isolated a partial cDNA from a Jurkat cell cDNA library
that appeared to encode a binding partner for p50Cool-1.
Data base analyses indicated that this cDNA fragment en-
coded a peptide that matched a portion of the proline-rich
domain of Cbl-b (Fig. 1), a member of the Cbl family that
was originally cloned from a ZR75-1 breast cancer cell cDNA
library [27]. Cbl-b is about 60% identical to c-Cbl and shares
all of the same functional motifs.
Based on this initial indicator from the yeast two-hybrid
screen, we then set out to determine whether Cbl-b binds to
the Cool proteins in mammalian cells. We used a speci¢c anti-
body raised against Cbl-b to immunoprecipitate the endoge-
Fig. 1. Yeast two-hybrid screen identi¢ed Cbl-b as a potential bind-
ing partner for the Cool proteins. A: Depiction of the di¡erent do-
main structures of Cbl-b. Both Cbl-b and c-Cbl contain the limit re-
gion that comprises the viral Cbl protein (v-Cbl), as well as ring-
¢nger (RF) and proline-rich (Pro-rich) domains, and carboxy-termi-
nal tyrosine phosphorylation (PY) sites. B: Comparison of the se-
quence deduced from the partial clone corresponding to the Cool-
binding protein with the corresponding sequences for human Cbl-b
and c-Cbl. Regions of amino acid identity are included within
boxes. Alignment was achieved using the Clustal X program.
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nous protein from a variety of human breast cancer cell lines
and then assayed for the presence of endogenous Cool by
Western blotting with rabbit antiserum that was raised against
the Cool-1 proteins [17]. As shown in Fig. 2A, we detected a
speci¢c interaction between Cbl-b and p85Cool-1 in every cell
type examined. We did not ¢nd p50Cool-1 in the Cbl-b im-
munoprecipitates, probably because it is typically present in
much lower abundance and is di⁄cult to detect relative to
p85Cool-1 [17].
Given the sequence similarity between Cbl-b and c-Cbl, it
was of interest to examine whether c-Cbl was also capable of
associating with the Cool proteins. When similar types of im-
munoprecipitation experiments were performed in human
breast cancer cells using an anti-c-Cbl antibody for immuno-
precipitation, followed by Western blotting with the anti-Cool
antiserum, we typically did not detect a speci¢c interaction
between c-Cbl and p85Cool-1 (Fig. 2B). In some experiments,
we did observe the co-immunoprecipitation of c-Cbl with
p85Cool-1, although this was infrequent. Thus, c-Cbl is ap-
parently a weaker binding partner for the Cool proteins com-
pared to Cbl-b, such that in human breast cancer cells Cbl-b
outcompetes c-Cbl for binding Cool. However, when Myc-
tagged p85Cool-1 and HA-tagged c-Cbl were co-expressed
in NIH 3T3 cells (which lacked Cbl-b), we were able to co-
immunoprecipitate p85Cool-1 and c-Cbl (Wu et al., submit-
ted).
Because the initial protein sequence obtained from our
yeast two-hybrid screen overlapped the proline-rich domain
of Cbl-b (Fig. 1), we examined whether the interactions be-
tween Cbl-b and the Cool proteins were mediated through the
Cool SH3 domain. The results presented in Fig. 2C suggest
that this is in fact the case. When a conserved tryptophan
residue within the SH3 domain of p85Cool-1 was mutated
to a lysine residue, the binding of Cbl-b to p85Cool-1 was
completely abolished. Like Cbl-b, c-Cbl contains a stretch of
proline residues and we have found that the p85Cool-
1(W43K) mutant is also incapable of co-immunoprecipitating
with HA-tagged c-Cbl in NIH 3T3 cells (Wu et al., submit-
ted).
The requirement of a functional SH3 domain for binding
the Cbl proteins indicates that each of the Cool proteins is
capable of such an interaction, as they either share a common
(p50Cool-1 and p85Cool-1) or highly similar (Cool-2) SH3
domain which they use to bind PAK [17]. This in turn sug-
gests that the Cbl proteins should compete with PAK for
binding the Cool proteins.
We examined potential competition between Cbl-b and
PAK for the Cool proteins by determining the e¡ects of
Cbl-b on the Cool-2-mediated activation of PAK. While it
was originally suggested that the Cool/Pix proteins acted as
upstream activators of Cdc42/Rac [18], we had not been able
to directly demonstrate nucleotide exchange activity for
p50Cool-1 or p85Cool-1 [17,29]. We now know that this is
due to the presence of a speci¢c sequence of 18 amino acid
residues that is immediately downstream of the PH domains
of the Cool-1 proteins but is missing in Cool-2 [29]. Cool-2 is
capable of acting as a guanine nucleotide exchange factor
(GEF [29]) and we have recently found that it is a highly
e¡ective GEF for Rac in cells (Feng et al., unpublished
data). This may explain how Cool-2 strongly stimulates
PAK activity [29]. The Cool-2-mediated activation of PAK
can be observed when immunoprecipitating PAK from COS
cells and then assaying its ability to phosphorylate MBP. An
example is shown in Fig. 3A, where Myc-tagged Cool-2 was
co-immunoprecipitated with either HA-tagged full-length
PAK3 or an HA-tagged PAK3 construct that lacks the kinase
domain (designated PAK3(vKD)). Phosphorylation of MBP
was only observed when full-length PAK3 was co-immuno-
precipitated with Cool-2, and not when PAK3(vKD) was co-
immunoprecipitated with the Cool-2 protein. Little or no
phosphorylation of MBP occurred when PAK3 was expressed
and assayed in the absence of Cool-2 (see Figs. 3C and 4B).
Fig. 2. Cbl-b binds Cool in human breast cancer cells. A: Endogenous Cbl-b was immunoprecipitated from the lysates of the di¡erent indicated
human breast cancer cells using a speci¢c anti-Cbl-b monoclonal antibody. The ¢nal lane represents 10% of the whole cell lysates from SKBR3
cells that was used for immunoprecipitation. PS represents pre-immune serum (control). The proteins were Western blotted and the blots were
probed with an antibody raised against p50Cool-1. Based on molecular weight standards, the band recognized by the anti-Cool antibody has
an apparent Mr of 85 kDa and thus corresponds to endogenous p85Cool-1/L-Pix. B: Endogenous Cbl-b, c-Cbl, and PAK were immunoprecipi-
tated from SKBR3 cells and assessed for the binding of endogenous p85Cool-1 by Western blotting using the anti-Cool antibody. PS represents
the pre-immune serum control. C: The SH3 domain of the Cool proteins is essential for binding Cbl-b. COS cells were transfected with plas-
mids expressing the indicated HA- or Myc-tagged proteins. Anti-HA immunoprecipitates (12CA5) (lanes 6^11, main panel) were Western blot-
ted with anti-Myc (9E10) to detect the presence of p85Cool-1. Lanes 1^5 represent 10% of the whole cell lysates used in the immunoprecipita-
tion reactions. The lower panel is an anti-HA blot (for HA-Cbl-b). The bands at V60 kDa in the immunoprecipitation experiments represent
IgG.
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An interesting question then concerns whether Cool-2 must be
able to bind PAK in order to mediate its activation. If so, the
competitive binding of Cbl-b to PAK should prevent Cool-2
from stimulating PAK activity.
In Fig. 3C (lower panel), we show the results of PAK3
assays performed under conditions where the relative levels
of Cbl-b to Cool-2 were signi¢cantly di¡erent. The expression
of Cool-2 together with PAK3, but in the absence of Cbl-b,
gave the expected strong stimulation of PAK activity (Fig.
3C, lower panel, lane 4), compared to cells expressing PAK3
alone (lane 1). In cells that expressed the lower level of Cbl-b
relative to PAK3 (Fig. 3C, lane 2), there was no detectable
e¡ect on PAK activity compared to cells that were not trans-
fected with Cbl-b, whereas in cells that expressed the higher
level of Cbl-b relative to PAK3 (Fig. 3C, lane 3), the ability of
Cool-2 to stimulate PAK activity was completely lost. Note
that the inhibition by Cbl-b is clearly detected, despite the fact
that a greater amount of PAK3 was assayed in this case (see
the upper panel in Fig. 3C).
The results presented in Fig. 3 indicate that Cbl-b compet-
itively inhibits the binding of Cool-2 to PAK. This also dem-
onstrates that the binding of Cool-2 to PAK is necessary for
Cool-2 to promote PAK activation. The ability of Cool-2 to
stimulate the GEF activity of Rac, as assayed by the Cool-2-
stimulated dissociation of [3H]GDP from Rac, does not re-
quire the binding of PAK to Cool-2 (Feng et al., unpublished
Fig. 3. Cbl-b inhibits Cool-2-stimulated PAK3 activity. A: COS
cells were transiently transfected with HA-PAK3 (0.5 Wg), HA-
PAK3 that lacks the kinase domain (designated vKD; residues
1^327) (2 Wg), and Myc-tagged Cool-2 (2 Wg) as indicated. The
upper panel represents the immunoprecipitation of the PAK con-
structs with anti-HA, followed by probing the blots with anti-HA,
to detect the relative amounts of PAK, and with anti-Myc to detect
Cool-2. The lower panel represents PAK activity measured in an
immune complex kinase assay using MBP as a substrate. B: COS
cells were transiently transfected with HA-PAK3 (0.5 Wg), HA-Cbl-b
(1.0 Wg, lane 2; 5.0 Wg, lane 3), and Myc-tagged Cool-2 (2 Wg) as in-
dicated. The upper panel was probed with anti-HA to detect the rel-
ative amounts of Cbl-b and PAK that were expressed, and the bot-
tom panel of the blot was probed with anti-Myc to detect Cool-2.
C: The upper panel shows the relative amounts of PAK3 assayed
for the di¡erent conditions and the lower panel compares PAK ac-
tivity assayed using MBP as substrate.
Fig. 4. A Cbl-b construct defective in binding Cool-2 does not in-
hibit Cool-2-stimulated PAK activity. A: COS cells were transiently
transfected with HA-PAK3 (0.5 Wg), Myc-tagged Cool-2 (2 Wg), and
either full-length Cbl-b (5 Wg) or a Cbl-b construct (5 Wg) that is
truncated at the end of the ring-¢nger domain and lacks the pro-
line-rich region responsible for binding Cool-2 (designated Cbl-b-
RF, residues 1^418). The lysates were then blotted with anti-HA to
detect PAK3, Cbl-b, and Cbl-b-RF, and with anti-Myc to detect
Cool-2. The lower bands seen in the Cbl-b lane (i.e. lane 3) repre-
sent some degradation products from Cbl-b. B: PAK3 assays were
performed as described in Fig. 3C.
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data). Rather, the requirement for Cool-2 to bind to PAK in
order to promote its activation might imply that PAK serves
to recruit Cool-2 to the proper cellular location so that Cool-
2-stimulated GDP^GTP exchange on Rac is directly trans-
lated into the stimulation of PAK activity by GTP-bound
Rac.
When experiments were performed using a Cbl-b protein
that lacks the Cool-binding site (i.e. the proline-rich domain),
as originally identi¢ed in our yeast two-hybrid screens, Cool-
2-mediated PAK activation was fully restored. Fig. 4 shows
the results of such an experiment. Comparisons of the ability
of Cool-2 to stimulate the PAK3-catalyzed phosphorylation
of MBP in the presence of either full-length Cbl-b, or a Cbl-b
construct that is truncated after the ring-¢nger domain and
thus lacks the proline-rich domain, are shown in the lower
panel of Fig. 4B (the upper panel compares the amount of
PAK3 assayed for each condition). It is clear that while excess
Cbl-b can strongly inhibit Cool-2-stimulated PAK activity
(compare lanes 2 and 3 in the lower panel of Fig. 4B), the
Cbl-b construct lacking the Cool-binding site shows no inhib-
itory e¡ects (compare lanes 2 and 4).
Recently, it has been reported that the Cbl proteins have E3
ubiquitin ligase activity and participate in the degradation of
EGF receptors [25,26], which may at least in part contribute
to their negative regulatory e¡ects on EGF receptor-coupled
signaling. Here we provide a possible mechanism for an in-
hibitory signaling activity conferred by the Cbl proteins that is
distinct from their ubiquitin ligase activity [30]. This occurs as
an outcome of the direct binding of the Cbl proteins to Cool-
2. Under those circumstances where the Rac GEF, Cool-2, is
able to bind to PAK, a serine/threonine kinase and a primary
signaling partner for Rac, a complex is formed that connects
the activation of Rac directly to the stimulation of PAK ac-
tivity. However, by competing with PAK for binding to Cool-
2, the Cbl proteins disrupt this connection and block Rac
activation and signaling through PAK. Thus, we suggest
that the Cbl proteins have the potential to serve in a dual
capacity to antagonize EGF receptor- or related tyrosine ki-
nase-coupled signaling activities, through their abilities to cat-
alyze receptor ubiquitination and to interfere with Cool-2/
Rac-mediated PAK activation.
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